3 Topics Patients Should Discuss With Their Oncology Teams

News
Article

An expert discusses three crucial conversations about cancer care that patients should have with their health care providers.

Open communication between patients and providers is essential in cancer care. In fact, there are three important conversations patients should be having with their clinicians, explained Dr. Eric Jonasch.

Research published in Supportive Care in Cancer found that for patients with cancer living in rural areas, those with higher patient-provider communication tended to experience greater social wellbeing and functional wellbeing than those with low or medium patient-provider communication.

MORE:3 Important Patient-Provider Discussions for Newly Diagnosed Kidney Cancer

Jonasch is a professor in the Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston. He recently sat down and outlined three important patient-provider discussions. They include: the goals of care and quality of life discussions; the type of treatment options that are available; and if there are any clinical trials that might be an option.

Transcript

First of all, obviously, what are the goals of care are really important. And these are different for every patient; some patients want a therapeutic effect and find that the side effect issues are secondary. Other patients are completely opposite. Some patients have goals in terms of what they want to be able to maintain an accomplish while they're on treatment. So I think having that sort of a goals-of-care conversation is really important to begin with set the stage.

Secondly, really, I think, getting a clearer idea of what the options are from a therapeutic perspective, so that the patient and the patient's family really know what those treatments are, what the logistics of receiving different types of treatments are (is important), because some therapies end up being much more onerous from a schedule perspective and from a time commitment perspective versus others.

Also, (it is important to discuss) what clinical trials and what research is out there, so their standard of care treatment, but what is there from a research perspective and asking the question, you know, your doctor, you're providing me with standard of care options, but what are their clinical trials? And would these clinical trials be for me? I think these are some of the key things that should be discussed, with the with the care team.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content